Part 1: Surya Singh, MD, on Biosimilar Rebates and Payer Decisions
September 2nd 2020Surya Singh, MD, president and owner of Singh Healthcare Advisors LLC in Lexington, Massachusetts, discussed how payers’ decisions regarding formulary lists affect patient out-of-pocket costs and access to biosimilars.
Part 2: Cheryl Larson on What Employers Can Do to Influence Health Plan Decisions
August 27th 2020Cheryl Larson, president and CEO of the Midwest Business Group on Health, based in Chicago, Illinois, discussed what employers can do to get biosimilars added to their formulary lists and ensure their pharmacy benefit managers (PBMs) aren’t taking advantage of them.
Part 1: Cheryl Larson on How Employers Are Taking on PBMs
August 25th 2020Cheryl Larson, president and CEO of Midwest Business Group on Health, based in Chicago, Illinois, discussed how some employers are taking on pharmacy benefit managers (PBMs) to get biosimilars added to their formularies and what it could mean for biosimilar savings going forward.
Part 2: Swaminathan P. Iyer, MD, Discusses Changing the Infrastructure of Drug Access
August 20th 2020Swaminathan P. Iyer, MD, a professor of medicine in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discussed oncology biologics that are too costly for patients whether the Doha Declaration, which would enable governments to license the manufacture of these products, is a viable option.
Part 1: Swaminathan P. Iyer, MD, Discusses Need for Biosimilars in India, US
August 18th 2020Swaminathan Iyer, MD, a professor of medicine in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, discussed the importance of biosimilars in India and the United States and the main concerns originator companies have regarding biosimilar competition.
Part 2: Nancy Globus on Whether or Not Biosimilar Naming Causes Confusion
August 13th 2020Nancy J. Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs (ACMA), discusses the truth behind 4-letter suffixes and product confusion among physicians and pharmacists.
Part 2: Axinn Patent Attorneys Discuss New Challenges for Insulins Under the BPCIA
July 23rd 2020Ted Mathias and Stacie Ropka, PhD, intellectual property law partners with Axinn, Veltrop and Harkrider LLP, discuss patent disputes and interchangeability designations with regard to insulin products under the Biologics Price Competition and Innovation Act (BPCIA). This is Part 2 of the interview. To watch Part 1, click here.
Rathore Discusses Study on Biosimilar Application Failures
July 22nd 2020The Center for Biosimilars® interviewed Anurag S. Rathore, PhD, whose team of investigators evaluated why applications for biosimilar approvals do not succeed. Large companies as well as small find the approval process challenging, but there is a learning curve that may be followed by more consistent approvals, he explains.
Part 1: Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
July 21st 2020Ted Mathias and Stacie Ropka, PhD, intellectual property law partners with Axinn Veltrop and Harkrider LLP, met with The Center for Biosimilars® to discuss how insulins will be regulated under the Biologics Price Competition and Innovation Act (BPCIA) versus the Hatch-Waxman Act, as well as the new challenges follow-on manufacturers will face.
Celltrion: Infliximab Biosimilar Shows Promise for COVID-19
July 14th 2020Byoungseo Choi, head of marketing for Celltrion Healthcare, discusses how Celltrion's infliximab biosimilar can aid in the treatment of coronavirus disease 2019 (COVID-19)–related inflammation, as well as the company’s launch plans for biosimilars through 2030.
Kathy Oubre: Other Players Complicate Biosimilar Use for Cancer Centers
July 2nd 2020Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center in Louisiana, president of the Louisiana Medical Group Management Association and member of the board of directors for the Community Oncology Alliance, discusses how payers, pharmacy benefit managers, and manufacturers make providing biosimilars complicated for patients and providers.
Ryan Haumschild, PharmD, Outlines Ways to Boost Physician Confidence in Biosimilars
July 1st 2020Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare in Atlanta, Georgia, discussed results to the survey he conducted on biosimilar utilization and planned initiatives about how to increase physician confidence in biosimilars.
Part 2: Nick Mitrokostas on the Race for the First Interchangeable Biosimilar
June 24th 2020Nick Mitrokostas, an intellectual property law attorney with Goodwin Proctor in Boston and editor-in-chief of Big Molecule Watch, discussed the building anticipation for the first interchangeable biosimilar and whether the FDA is doing enough to facilitate the development of more biosimilars and quell anticompetitive practices.
Part 1: Nick Mitrokostas on How COVID-19, FDA Rule Changes Are Shaping the Biosimilar Market
June 23rd 2020Nick Mitrokostas, an intellectual property law attorney with Goodwin Proctor in Boston and editor in chief of Big Molecule Watch, discussed the impact on the US biosimilar market from the coronavirus disease 2019 (COVID-19) pandemic and the recent change to the Biologics Price Competition and Innovation Act (BPCIA).
Part 2: Christine Simmon Discusses Payer Influence on Provider Behavior
June 18th 2020Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the Association for Accessible Medicines (AAM) discussed the new pathway for insulin biosimilars and the struggles between payers and providers over biosimilar choice.
Part 1: Christine Simmon Discusses the Individual Mandate and Biosimilars
June 16th 2020Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the Association for Accessible Medicines (AAM) discusses potential legislation that the AAM is advocating for and how the upcoming election and Supreme Court decision will affect biosimilars.
Joseph Fuhr, PhD, Discusses Competition for the Growing Biosimilar Market
June 10th 2020Joseph P. Fuhr Jr, PhD, professor emeritus of economics at Widener University in Chester, Pennsylvania, and an expert on antitrust health economics and pharmacoeconomics discusses how future biosimilar competition will affect consumers and market development.
Ha Kung Wong and April Breyer Menon Discuss Promising and Not-so-Promising Biosimilar Legislation
June 5th 2020An extended interview with Ha Kung Wong, JD, an intellectual property law attorney and partner at Venable Fitzpatrick in New York and April Breyer Menon, JD, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago discussing potential biosimilars legislation.
Part 2: Ali McBride Discusses Initiatives to Improve Physician Education on Biosimilars
May 25th 2020Ali McBride, PharmD, MS, BCOP, clinical coordinator of Hematology and Oncology in the Department of Pharmacy at the University of Arizona Cancer Center and past president of the Association of Community Cancer Centers (ACCC), discusses physician struggles tied to biosimilar utilization, the upcoming initiatives for the ACCC Biosimilars Center, and why physicians should be keeping an eye on biosimilars.
Part 1: Ali McBride Discusses ACCC Initiatives and Biosimilar Uptake
May 18th 2020Ali McBride, PharmD, MS, BCOP, clinical coordinator of Hematology and Oncology in the Department of Pharmacy at the University of Arizona Cancer Center and past president of the Association of Community Cancer Centers (ACCC), discusses the anticipated growth for the US biosimilar market and what the ACCC is doing to further uptake efforts.
Part 2: Jim Koeller Discusses the Complexities of Multiple Biosimilars
May 13th 2020Jim M. Koeller, MS, a professor of pharmacotherapy and member of the Center for Pharmacoeconomic Studies in the College of Pharmacy at the University of Texas at Austin, discusses the complexities of an institution taking on multiple biosimilars and how payers can make the process easier.
Roman Drai Discusses Geropharm's Biosimilar Pursuits
May 12th 2020Roman Drai, MD, PhD, deputy director and head of clinical operations at Geropharm, discussed Geropharm’s budding biosimilar pipeline and the company’s international pursuits during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.
Part 1: Jim Koeller Talks Payer Influence on Biosimilars
May 11th 2020Jim Koeller, a professor of pharmacotherapy and member of the Center for Pharmacoeconomic Studies in the College of Pharmacy at the University of Texas at Austin, discusses how payers influence biosimilar prescriptions and the pressure to lower drug costs for patients.
Part 3: Axinn Attorneys Discuss Patent Exclusivity and the BPCIA
May 8th 2020Ted Mathias and Stacie Ropka, PhD, both patent attorneys and partners at Axinn, Veltrop and Harkrider LLP, discuss patent exclusivity for biological drugs and other important issues that need to be addressed whether or not the ACA and the Biologics Price Competition and Innovation Act (BPCIA) are ruled invalid.
Part 2: Axinn Patent Attorneys Discuss Fallout From Challenges to the ACA
May 6th 2020Ted Mathias and Stacie Ropka, PhD, patent attorneys and partners at Axinn, Veltrop, and Harkrider LLP, discuss past and future court decisions that leave the Affordable Care Act (ACA) in jeopardy and what could happen to the Biologics Price Competition and Innovation Act (BPCIA) as a result.
Molly Burich: How to Improve Biosimilar Uptake
May 5th 2020Molly Burich, MS, head of public policy at Boehringer Ingelheim, discusses several tactics that would help increase biosimilar uptake in the United States and get around current obstacles during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.